Flavodoxin inhibitors to kill resistant bacteria (FLAV4AMR)

This transnational collaboration gathers the expertise and resources required to address lead improvement to the point of producing novel antibiotics ready for clinical trials, and to clarify the overall importance of flavodoxin as a novel drug target.

Ongoing project

The project has two goals:
1. To culminate the improvement of inhibitors of the flavodoxin from H. pylori, which have shown efficacy against reference and clinical strains (including a clarithromycin-resistant one) and in a mice model.
2. To determine the relevance of flavodoxin as a novel drug target to fight bacteria which pose problems associated to antimicrobial resistance.


Project partners

  • Javier Sancho, Javier Sancho, Spain (Coordinator)
  • Eliette Touati, Pasteur Institute, France
  • Ultrich E Schaible, Research Center Borstel, Germany
  • Alain Bousquet-Melou, Ecole Nationale Vétérinaire de Toulouse, France